- 1 Metabolomics of IgE-Mediated Food Allergy and Oral Immunotherapy Outcomes based on
- 2 Metabolomic Profiling
- 3 Authors: Yamini V. Virkud,^{1,2,3,4} Jennifer N. Styles¹, Rachel S. Kelly,^{3,4} Sarita U. Patil ^{2,3,5}, Bert
- 4 Ruiter^{2,3}, Neal P. Smith², Clary Clish,⁵ Craig E. Wheelock,⁶ Juan C. Celedón,⁷ Augusto A.
- 5 Litonjua, ^{3,4} Supinda Bunyavanich,⁸ Scott T. Weiss,^{3,4} Erin S. Baker,⁹ Jessica A. Lasky-Su^{*},^{3,4}
- 6 Wayne G. Shreffler*^{2,3,5}

7 ***co-senior authorship**

8 Affiliations:

- University of North Carolina, Chapel Hill. Department of Pediatrics, Division of Allergy and
 Immunology, Food Allergy Initiative. Chapel Hill, NC
- Massachusetts General Hospital for Children, Food Allergy Center. Department of Pediatrics,
 Massachusetts General Hospital, Boston, MA
- 13 3. Harvard Medical School, Boston, MA
- 14 4. Channing Division of Network Medicine, Brigham & Women's Hospital, Boston, MA
- 15 5. Broad Institute, Cambridge, MA
- Karolinska University Hospital, Unit of Integrative Metabolomics, Institute of Environmental
 Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and
 Allergy. Stockholm, Sweden.
- Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center. Division of Pulmonary Medicine. University of Pittsburgh, Pittsburgh, PA 15260, USA
- 8. Icahn School of Medicine at Mount Sinai. Department of Genetics & Genomic Sciences and
 Department of Pediatrics. New York, NY
- 23 9. University of North Carolina, Chapel Hill. Department of Chemistry. Chapel Hill, NC
- 24
- 25

26 Corresponding author:

- 27 Yamini V. Virkud, virkud@unc.edu
- 28 University of North Carolina
- 29 101 Manning Drive, CB#7231
- 30 Chapel Hill, NC 27599-7231
- 31
- 32 Clinical Trial or Protocol number associated with this study: NCT01324401 (PNOIT),
- 33 NCT00920621 (VDAART)
- 34 **Conflicts of Interest:** JLS is a scientific consultant to Precion Inc. and TruDiagnostic Inc. AAL
- contributes to UpToDate, Inc. author of online education, royalties totaling not more than \$3000 per
- 36 year. STW receives royalties from UpToDate and is on the board of Histolix a digital pathology
- 37 company. JCC has received research materials (inhaled steroids) from Merck, in order to provide
- 38 medications free of cost to participants in an NIH-funded study, unrelated to the current work. The
- remaining authors have no conflicts of interest to disclose.
- 40

41 Funding/Acknowledgments: The Genetics of Asthma in Costa Rica Study was supported by the National Institutes of Health (Grants HL066289, P01HL13225, R01HL123915). Vitamin D Antenatal 42 Asthma Reduction Trial (VDAART) was supported by R01HL123546, R01HL091528, U01HL091528, 43 and UH3ODO023268 from the National Heart, Lung, and Blood Institute (NHLBI); U54TR001012 from 44 the National Centers for Advancing Translational Sciences; and U19AI168643 from the NIAID. GACRS 45 & VDAART metabolomic profiling and additional analyses were supported by R01HL123915. 46 R01HL141826, and R01HL155742. The Peanut Oral Immunotherapy (PNOIT) study clinical trial work 47 48 was performed at the Harvard Clinical and Translational Science Center supported by Grant Numbers 49 1UL1TR001102. 8UL1TR000170 from the National Center for Advancing Translational Science, and 50 1UL1 RR025758 from the National Center for Research Resources. PNOIT metabolomics profiling was supported by the 2014 ARTrust Minigrant. This work is also supported by NIH NIAID (grant K23-51 AI130408 for YVV, T32AI007062 for JNS, 1R01AI155630 for SUP), and NHLBI (K01 HL146980 for 52

- 53 RSK). CEW was supported by the Swedish Heart-Lung Foundation (HLF 20230463, HLF 20210519).
- 54 SB is supported by the NIH NIAID (UM1 AI173380, U19 AI136053, R01 AI147028, U01 AI160082). EB
- is supported by NIEHS (P42ES027704) and NIGMS (R01GM141277 and RM1GM145416).

56 ORCIDs:

- 57 Yamini V. Virkud,^{1,2,3,4} (https://orcid.org/0000-0001-7328-7215)
- 58 Jennifer N. Styles¹, (https://orcid.org/0000-0001-6777-1334)
- 59 Rachel S. Kelly,^{3,4}, (https://orcid.org/0000-0003-3023-1822)
- 60 Sarita U. Patil ^{2,3,5}, (https://orcid.org/0000-0002-2172-2286)
- 61 Bert Ruiter^{2,3}, (https://orcid.org/0000-0003-3945-3202)
- 62 Neal P. Smith², (https://orcid.org/0000-0003-1394-3158)
- 63 Clary Clish,⁵ (https://orcid.org/0000-0001-8259-9245)
- 64 Craig E. Wheelock,⁶ (https://orcid.org/0000-0002-8113-0653)
- 65 Juan C. Celedón,⁷ (https://orcid.org/0000-0002-6139-5320)
- 66 Augusto A. Litonjua, ^{3,4} (https://orcid.org/0000-0003-0422-5875)
- 67 Supinda Bunyavanich,⁸ (https://orcid.org/0000-0001-6108-439X)
- 68 Scott T. Weiss,^{3,4} (https://orcid.org/0000-0001-7196-303X)
- 69 Erin S. Baker,⁹ (https://orcid.org/0000-0001-5246-2213)
- 70 Jessica A. Lasky-Su*,^{3,4} (https://orcid.org/0000-0001-6236-4705)
- 71 Wayne G. Shreffler*^{2,3,5} (https://orcid.org/0000-0001-6465-137X)

72 Abstract:

- 73 Background: The immunometabolic mechanisms underlying variable responses to oral immunotherapy
- 74 (OIT) in patients with IgE-mediated food allergy are unknown.
- 75 *Objective*: To identify novel pathways associated with tolerance in food allergy, we used metabolomic
- profiling to find pathways important for food allergy in multi-ethnic cohorts and responses to OIT.
- 77 *Methods:* Untargeted plasma metabolomics data were generated from the VDAART healthy infant
- cohort (N=384), a Costa Rican cohort of children with asthma (N=1040), and a peanut OIT trial (N=20)
- 79 evaluating sustained unresponsiveness (SU, protection that lasts after therapy) versus transient
- 80 desensitization (TD, protection that ends immediately afterwards). Generalized linear regression
- 81 modeling and pathway enrichment analysis identified metabolites associated with food allergy and OIT
- 82 outcomes.
- 83 Results: Compared with unaffected children, those with food allergy were more likely to have
- 84 metabolomic profiles with altered histidines and increased bile acids. Eicosanoids (e.g., arachidonic
- acid derivatives) (q= 2.4×10^{-20}) and linoleic acid derivatives (q= 3.8×10^{-5}) pathways decreased over time
- on OIT. Comparing SU versus TD revealed differing concentrations of bile acids ($q=4.1x10^{-8}$),
- eicosanoids (q=7.9x10⁻⁷), and histidine pathways (q=0.015). In particular, the bile acid lithocholate
- 88 (4.97[1.93,16.14], p=0.0027), the eicosanoid leukotriene B4 (3.21[1.38,8.38], p=0.01), and the histidine
- metabolite urocanic acid (22.13[3.98,194.67], p=0.0015) were higher in SU.
- 90 *Conclusions:* We observed distinct profiles of bile acids, histidines, and eicosanoids that vary among
- 91 patients with food allergy, over time on OIT and between SU and TD. Participants with SU had higher
- 92 levels of metabolites such as lithocholate and urocanic acid, which have immunomodulatory roles in
- 83 key T-cell subsets, suggesting potential mechanisms of tolerance in immunotherapy.

94 Key Messages

- 95 Compared with unaffected controls, children with food allergy demonstrated higher levels of bile
 96 acids and distinct histidine/urocanic acid profiles, suggesting a potential role of these
 97 metabolites in food allergy.
- In participants receiving oral immunotherapy for food allergy, those who were able to maintain
 tolerance -even after stopping therapy- had lower overall levels of bile acid and histidine
 metabolites, with the exception of lithocholic acid and urocanic acid, two metabolites that have
- 101 roles in T cell differentiation that may increase the likelihood of remission in immunotherapy.

102 Capsule summary

- 103 This is the first study of plasma metabolomic profiles of responses to OIT in individuals with IgE-
- 104 mediated food allergy. Identification of immunomodulatory metabolites in allergic tolerance may help 105 identify mechanisms of tolerance and guide future therapeutic development.
- 106 Key Words:

- 107 Food Allergy, Immunotherapy, IgE-mediated food allergy, Metabolomics, Secondary bile acids
- 108 Lithocholic acid, Lithocholate, Eicosanoids, Arachidonic acid, Bile acids, Urocanic acid, Histidines;
- 109 Sustained Unresponsiveness; Transient Desensitization; Remission

110 Graphical Abstract:

111



112 Introduction:

The prevalence of potentially life-threatening immunoglobulin E (IgE)-mediated food allergies is currently estimated at 8-10%, and as the prevalence continues to rise, the need for treatment options becomes more urgent.¹⁻³ The development of novel therapies requires a comprehensive understanding of immune tolerance to allergens, including how tolerance differs between individuals with and without food allergies, and how this is modified by treatment.

118

Although oral immunotherapy (OIT) was approved as the first and only treatment for IgE-mediated

- peanut allergies in 2020, the effects of such treatment can have limited duration and lead to allergic
- adverse events.⁴ Most individuals with food allergy (~50-75%) are capable of achieving transient
 desensitization, a state where daily OIT protects against accidental exposure to allergen by increasing
- the eliciting dose for a reaction. While estimates vary by study, only approximately one-third of children
- demonstrate sustained unresponsiveness (also described as remission), a state of clinical tolerance to
- 125 large doses of allergen persisting at least weeks after cessation of regular allergen consumption.^{5, 6}
- 126 Studies of patients on OIT therefore provide a unique insight into the pathophysiology of allergen-
- 127 specific immunity. Furthermore, while the adaptive immunity underlying food allergies and therapeutic
- responses have been studied extensively, little is known about the immunometabolism (the interaction
- 129 between immunity and metabolism) of the modification of tolerance to food allergens.⁷⁻⁹
- 130

131 Metabolomics, defined as study of small molecule cellular substrates, intermediates and products of

- cellular metabolism, can be used to gauge the physiologic state of an organism and can reflect the
- interaction of the genome, transcriptome, proteome, microbiome, and environmental influences on
- disease.^{10, 11} Studies support the utility of metabolomic analyses in identifying pathways associated with
- food allergy, while several investigations have explored the evolution of metabolomic profiles on other
 types of aeroallergen sublingual and subcutaneous immunotherapy.^{9, 12-21} To date, one study has
- examined water soluble metabolites in the stool in the setting of food immunotherapy, and none have
- 138 studied the plasma metabolome in humans.²².
- 139

140 Our main objectives were to (1) examine metabolomic profiles of individuals with food allergy in multi-

- 141 ethnic cohorts (Genetics of Asthma in Costa Rica (GACRS) and the Vitamin D Antenatal Asthma
- 142 Reduction Trial (VDAART) infant cohort) to identify key pathways of interest, (2) explore how those and
- other metabolomic pathways evolve with OIT (using the Peanut Oral Immunotherapy trial (PNOIT)),
- and (3) associate the metabolomic profiles with therapeutic OIT outcomes (**Figure 1**). We used
- 145 longitudinal sampling to define pathophysiologic differences between those who develop transient
- desensitization versus sustained unresponsiveness while on OIT, to reveal novel mechanisms in
- 147 immune tolerance and inform future adjunctive therapies that may shift the response to OIT towards
- 148 longer-lasting protection.
- 149



150

151 Figure 1: Overview of Cohort Study Design and Analysis in 3 studies. Top: To study the metabolomics of food allergy, 2 152 cohorts, the Genetics of Asthma in Costa Rica (GACRS) and the Vitamin D Antenatal Asthma Reduction Trial (VDAART) were 153 used. Food allergy status was determined based on available clinical data (self-report for GACRS and detailed food allergy 154 questionnaire for VDAART). Untargeted metabolomic profiles were compared between participants with food allergy and 155 unaffected controls to identify key metabolites and subclasses of interest. Bottom: To study the metabolomics of OIT responses, 156 we used the Peanut Oral Immunotherapy trial (PNOIT), where participants underwent 56 weeks of peanut immunotherapy, 157 followed by 4 weeks of avoidance to determine who could maintain the protection of OIT after stopping (sustained 158 unresponsiveness, SU) versus who lost protection soon after stopping (transient desensitization, TD), as determined by oral 159 food challenges to full servings of peanut. Untargeted metabolomics was performed on the SU and TD groups to determine 160 metabolites that changed over time on OIT versus those that differed between SU and TD groups. Created with BioRender.com. 161

162 **METHODS**:

163 Study Populations:

Metabolomics data from three populations was compiled to address our objectives: (1) the Genetics of Asthma in Costa Rica Study (GACRS),²³⁻²⁶ (2) the Vitamin D Antenatal Asthma Reduction Trial (VDAART),²⁷ and (3) the Peanut Oral Immunotherapy (PNOIT) trial.²⁸

167

GACRS: Participants in the GACRS are members of a semi-isolated Latin American population from
 the Central Valley of Costa Rica, which has one of the highest rates of asthma worldwide (24% in
 children).²³⁻²⁵ Children ages 6-14 years were eligible for the study if they had asthma (physician-

diagnosed asthma and ≥2 respiratory symptoms or asthma attacks in the prior year) and a high

probability of having ≥6 great-grandparents born in the Central Valley of Costa Rica. A total of 1,189

children with asthma and their parents (i.e., 383 parent-child trios) were enrolled. The parents of

174 participating children completed extensive questionnaires, including a slightly modified and translated

- version of the questionnaire used in the Collaborative Study on the Genetics of Asthma²⁹. Metabolomic
 profiling was available for 1159 participants, and of those food allergy data were available for 1040
- 177 participants.

VDAART: The pediatric cohort of VDAART comprises the infants of mothers who were prenatally randomized to Vitamin D supplementation versus placebo in the multi-center trial (ClinicalTrials.gov ID NCT00920621).²⁷ All infants had a family history of asthma, eczema or allergic rhinitis in at least one biological parent. Families completed comprehensive questionnaires with detailed phenotyping of allergic diseases, including food allergy. The original study enrolled 881 mothers and their infants. We used metabolomic data (available for 411 participants) from plasma samples collected at age 3, to

study the association with food allergy at that age (available for 384 participants).

PNOIT: Pediatric participants (aged 7-21) enrolled in an open-label interventional peanut OIT trial,
 which involved the administration of gradually increasing doses of peanut allergen in order to decrease
 patients' sensitivity to peanut allergen (ClinicalTrials.gov ID NCT01324401).²⁸ Participants underwent a
 buildue abase where the summer a size a second se

- buildup phase where they were given incrementally increasing amounts of peanut protein, followed by a maintenance period with a daily dose of 4 grams. After 12 weeks of maintenance, participants
- maintenance period with a daily dose of 4 grams. After 12 weeks of maintenance, participants
 underwent an oral food challenge (OFC1), followed by 1 month of peanut avoidance. A final double-
- blind, placebo controlled food challenge (OFC2) was performed to assess transient desensitization
- 192 (those who failed OFC2) versus sustained unresponsiveness (those who passed OFC2). Blood
- 193 sampling for metabolome datasets occurred at baseline, early build-up (at the peak of AEs), OFC1, and
- final OFC2 and was conducted for those with sufficient sample who developed transient desensitizationor sustained unresponsiveness (n=20).
- 196 For all three cohorts, written parental consent on behalf of the child and child's assent, if age
- appropriate, were obtained. All three studies were approved by the trial sites Institutional Review

Boards. Further study design details are available in the original publications for each of the studies.²⁶⁻²⁸

199

200 Food Allergy Case identification

GACRS: The parents of study participants were asked by questionnaire if their child experienced a
 food allergy and to which food, and we defined cases as parental report of an allergy to one of the 8
 most common food allergens (milk, soy, egg, wheat, fish, shellfish, peanuts, tree nuts). Unaffected
 controls were those whose parents did not report food allergy. Participants with a report of a food
 allergy to an atypical allergen were excluded.

206 *VDAART:* Participants were given a detailed food allergy questionnaire which included questions 207 about suspected food allergies, symptoms associated with reactions, positive testing by skin test or

serum IgE test, and prescription with an epinephrine auto-injector. Some patients also had

209 corroborating specific IgE levels for foods. Patients with a convincing history (report allergen triggering

210 hives, swelling, cough, wheeze, vomiting, diarrhea) and evidence of sensitization (by positive blood IgE

or reported positive skin or blood testing) were reviewed by an allergist and included as cases.

212 Unaffected controls were those who did not report food allergy, and anyone reporting a food allergy but

213 not meeting criteria for diagnosis was excluded.

PNOIT: Inclusion criteria included objective symptoms after peanut ingestion, and either a peanut specific IgE >10 kU/L or elevated peanut-specific skin prick test >8 mm. All patients demonstrated IgE mediated symptoms during the early dosing of OIT, confirming the presence of true IgE-mediated food
 allergy.²⁸

218

219 Untargeted Metabolomics

220 Plasma samples were collected from all three populations, and metabolomic profiling was performed 221 by the Clish laboratory at the Broad Institute for GACRS and PNOIT, and by Metabolon Inc for 222 VDAART, Liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) methods were used to examine 4 classes of metabolites: 1) hydrophilic interaction liquid chromatography (HILIC)-223 MS/MS in positive ion mode (e.g., amino acids); (2) HILIC-MS/MS in negative ion mode (e.g., cAMP); 224 (3) C8 reversed phase LC-MS/MS for lipids (e.g., steroids), and (4) C18 reversed phase LC-MS/MS for 225 free fatty acids, (e.g., bile acids and eicosanoids). Features were indexed by their mass-to-charge ratio 226 and LC retention time and metabolite identities were confirmed using known standards.^{30, 31} All features 227 were log transformed to normalization and pareto-scaled to reduce the variation in fold change 228 229 differences between the features. To ensure uniform classification of metabolite subclasses between 230 the three cohorts, the Relational Database of Metabolic Pathways (RaMP) was used to identify the chemical subclass of each metabolite based on The Human Metabolome Database identifiers (HMDB 231 v.5.0).^{32, 33} 232

233

234 Statistical Analysis

Comparisons of demographics were conducted using chi-square or Fisher's exact tests, between 235 individuals with food allergy and unaffected controls, and also between patients with sustained 236 237 unresponsiveness versus transient desensitization. For GACRS and VDAART, we constructed 238 generalized linear models for each cohort separately to assess the association of metabolites with 239 reported food allergy, with adjustment for sex, age at blood collection, and for VDAART, race (Black, White, Asian, Other). For PNOIT, we used generalized linear regression (GLM) modeling, with 240 adjustment for age, to identify significant metabolites, with linear regression to determine metabolites 241 varying with time on OIT (from baseline to post-OIT), and logistic regression to identify metabolites 242 associated with outcome (transient desensitization versus sustained unresponsiveness), adjusted for 243 time on OIT from baseline to post-OIT. To summarize findings in PNOIT, we defined a set of key 244 pathways of interest based on biological significance in atopic disease (polyunsaturated fatty acids, 245 246 which include arachidonic acid metabolites, and sphingolipids), and based on top metabolite 247 subclasses that were altered in the setting of food allergy compared to unaffected controls from VDAART & GACRS. The full set of findings are included in the corresponding supplemental figures for 248 249 each set of analyses. Pathway analysis was performed using both chemical enrichment analysis (reported from the metabolite subclass) and biological pathway enrichment (based on biological 250 pathways from KEGG from HMDB v5.0, Reactome v85, and WikiPathways v20230710) using the 251 RaMP v2.3.0 (RaMP-DB R package).^{32, 34-36} All subclasses were defined using ClassyFire structural 252 classification, from HMDB v5.0.^{34, 37} To capture the full range of potentially relevant subclasses and 253 254 pathways, individual metabolites were reported based on a nominal significance of p<0.05, while 255 chemical subclasses and biological pathways were reported using FDR corrected significance of p<0.05. All analyses were performed using R 4.2.2.³⁸ Metabolomic data are available through the 256 dbGaP for GACRS, the ECHO consortium for VDAART, and Metabolomics Workbench for PNOIT.³⁹⁻⁴¹ 257

258

259 **RESULTS**:

Population demographics of three studies: two observational cohorts, GACRS and VDAART, and the PNOIT interventional trial

We used 2 observational cohorts, GACRS (n=1040 children with asthma) and VDAART (n=384 healthy 262 infants) to study the metabolomics of food allergy. The prevalence of reported food allergy in GACRS 263 was 5% (57/1040), while the prevalence of reported, validated, food allergy in VDAART was 6% 264 265 (22/384) (Table 1). Both populations were approximately 40% female; differences in racial/ethnicity 266 demographics were consistent with those between the countries of each study. Regarding atopic disease, the GACRS cohort had higher proportions of allergic rhinitis, whereas, the VDAART cohort 267 had higher percentages of eczema, consistent with the older versus younger ages of each cohort. 268 Approximately a guarter of the VDAART cohort experienced asthma/persistent wheeze by age 3, 269

compared with all reporting asthma symptoms in GACRS due to study design.

From the original PNOIT trial cohort,²⁸ 30 participants were enrolled, 27 completed treatment, and 13

272 participants developed transient desensitization (TD) compared to 9 with sustained unresponsiveness

273 (SU), and 5 participants experienced treatment failure. Metabolomic profiling was performed on 11 of

13 participants found to have transient desensitization (TD) and all 9 participants with sustained

275 unresponsiveness (SU); 2 samples from participants who developed TD were not included in

- 276 metabolomic profiling due to inadequate sample volumes. All participants in the PNOIT interventional
- trial had IgE-mediated food allergy by study design, and rates of asthma and allergic rhinitis were
- similar to those seen in the food-allergic population of VDAART (Table 1).

Genetics of Asthma in Costa Rica Study (GACRS)							
	Overall	Food Allergic	Unaffected	p-value			
	N=1040	(n=57)	Controls (n=983)				
Male (%)	619 (60%)	28 (49%)	591 (60%)	0.13			
Age at Sampling	9.2 (1.9)	9.0 (1.8)	9.3 (1.9)	0.39			
(years)							
Hispanic/Latinx	1040 (100%)	57 (100%)	983 (100%)	1.00			
Physician							
Diagnosed							
Asthma	1012 (97%)	55 (97%)	957 (97%)	1.00			
Allergic Rhinitis	335 (32%)	24 (42%)	311 (32%)	0.14			
Eczema	45 (4%)	6 (11%)	39 (4%)	0.04			
Vitamin D Antenatal Asthma Reduction Trial (VDAART)							
	Overall	Food Allergic	Unaffected	p-value			
	N=384	(n=22)	Controls (n=362)				
Male (%)	207 (54%)	12 (55%)	195 (54%)	1.00			
Age at Sampling	3.0 (0.09)	3.0 (0.1)	3.0 (0.09)	0.30			
(years)							
Race				0.11			
Black	186 (48%)	16 (73%)	170 (47%)				
White	125 (33%)	4 (18%)	121 (33%)				
Asian	22 (6%)	0 (0%)	22 (6%)				

Other	51 (13%)	2 (9%)	49 (14%)				
Hispanic/Latinx	126 (33%)	7 (32%)	119 (33%)	1.00			
Reported Asthma/	100 (26%)	15 (68%)	85 (24%)	<0.001			
Wheeze by age 3							
Physician							
Diagnosed							
Asthma	53 (14%)	12 (55%)	41 (11%)	<0.001			
Allergic Rhinitis	72 (19%)	11 (50%)	61 (17%)	<0.001			
Eczema	184 (48%)	22 (100%)	162 (45%)	<0.001			
Peanut Oral Immunotherapy Trial (PNOIT)							
	Overall	Sustained	Transient	p-value			
	N=20	Unresponsiveness	Desensitization	-			
		(SU) (n=9)	(TD) (n=11)				
Male (%)	15 (75%)	7 (78%)	8 (73%)	1.00			
Mean Age at	9.9 (2.1)	9.8 (2.3)	10.0 (2.1)	0.81			
Enrollment (years							
(SD))							
Race				0.40			
Asian	2 (10%)	1 (11%)	1 (9%)				
White	16 (80%)	8 (89%)	8 (73%)				
Other	2 (10%)	0 (0%)	2 (18%)				
Hispanic/Latinx	1 (5%)	0 (0%)	1 (9%)	1.00			
Allergic	· ·	· ·	· ·				
comorbidities							
Asthma	8 (40%)	3 (33%)	5 (45%)	0.93			
Allergic Rhinitis	12 (60%)	7 (78%)	5 (45%)	0.31			
Eczema	11 (55%)	3 (33%)	8 (73%)	0.19			
	· · ·						

Table 1: Demographics of GACRS, VDAART, and PNOIT studies. For GACRS, race was not collected from the Costa
 Rican population.

Food allergy in GACRS and VDAART associated with alterations in bile acid and histidine metabolism

After quality control measures, 595 named metabolites in GACRS and 655 in VDAART were available

for analysis. Regression analysis revealed that 16 (3%) metabolites in GACRS and 17 (3%)

285 metabolites in VDAART were associated with food allergy (Figure 2). Among these metabolites, the

most common subclasses included amino acids (11 metabolites) and bile acids (8 metabolites). Within

the amino acid pathway, histidine metabolism was the most prominent, with 2 metabolites increased

among individuals with food allergy individuals (N-acetyl histidine and urocanic acid, (range of odds

ratios (OR) 1.70-4.08, and range of p-values 0.017-0.018), and one metabolite, ergothioneine (OR

290 0.17, p=0.023) increased in unaffected controls. Among bile acids, metabolites included both primary

and secondary bile acids, and all 8 were increased in those with food allergy (range of OR: 1.13-3.44,

range of p-values: 0.0002-0.04). Based on these findings, we included bile acids and histidine

293 metabolites in our list of curated pathways to study in OIT.

Metabolites	OR [95% CI]	p-value		Dataset
Amino acids, peptides, and analogues				
N-acetylhistidine (Histidine Metabolism)	4.08 [1.27, 13.08]	0.018	-	VDAART
Urocanic acid (Histidine Metabolism)	1.70 [1.09, 2.60]	0.017	⊢ ,	GACRS
Ergothioneine (Histidine Metabolism)	0.17 [0.04, 0.79]	0.023	⊢	VDAART
Aspartic acid (Alanine and Aspartate Metabolism)	0.70 [0.48, 0.98]	0.048	⊢ ■-	GACRS
N-Acetyl-L-Alanine (Alanine and Aspartate Metabolism)	0.09 [0.01, 0.81]	0.033	—	GACRS
Phenylacetylglycine (Glycine, Serine and Threonine Metabolism)	3.13 [1.33, 7.36]	0.009	├■	VDAART
Dimethylglycine (Glycine, Serine and Threonine Metabolism)	0.35 [0.13, 0.89]	0.030	├──■ ──┤	GACRS
Isobutyrylcarnitine (C4) (Leucine, Isoleucine and Valine Metabolism)	4.28 [1.15, 15.91]	0.030	├ ── ■ ─	VDAART
3-hydroxyisobutyrate (Leucine, Isoleucine and Valine Metabolism)	4.24 [1.41, 12.79]	0.010	⊢	VDAART
N6,N6,N6-trimethyllysine (Lysine Metabolism)	3.15 [1.03, 9.61]	0.044	⊢	VDAART
Pipecolic acid (Lysine Metabolism)	1.51 [1.04, 2.21]	0.032	⊢ ∎-	GACRS
5-methylthioadenosine (MTA) (Polyamine Metabolism)	3.42 [1.34, 8.73]	0.010		VDAART
Tryptophan betaine (Tryptophan Metabolism)	0.34 [0.12, 0.97]	0.043	⊢_∎	VDAART
Bile acids, alcohols and derivatives				
Glycochenodeoxycholate 3-sulfate	3.44 [1.26, 9.37]	0.016	⊢	VDAART
Glycoursodeoxycholate sulfate	3.26 [1.30, 8.16]	0.012		VDAART
Glycoursodeoxycholate	3.14 [1.26, 7.86]	0.014	∎	VDAART
Deoxycholic acid glucuronide	2.65 [1.13, 6.23]	0.026		VDAART
Tauroursodeoxycholate	2.50 [1.04, 6.00]	0.040	■	VDAART
Glycocholic acid	1.44 [1.18, 1.73]	0.0002	H	GACRS
Glycochenodeoxycholic acid	1.37 [1.05, 1.74]	0.014		GACRS
Taurocholic acid	1.13 [1.04, 1.23]	0.003	• • • • •	GACRS
Nucleosides, nucleotides, and analogues				
Pseudouridine	6.42 [1.07, 38.37]	0.042		VDAART
Uridine	3.53 [1.01, 12.24]	0.047		GACRS
Xanthosine	1.25 [1.02, 1.50]	0.022	—	GACRS
Tricarboxylic acids and derivatives				
Aconitate [cis or trans]	5.70 [1.37, 23.71]	0.017	■	VDAART
Citric acid/Isocitric acid	0.35 [0.13, 0.91]	0.036		GACRS
Aconitic acid	0.24 [0.07, 0.82]	0.024		GACRS
Fatty acids and conjugates				
N-Oleoyl Dopamine	1.35 [1.05, 1.71]	0.013		GACRS
N-Arachidonoyl Dopamine	1.33 [1.04, 1.68]	0.017		GACRS
Other Subclasses				
Alpha-tocopherol (Quinone and hydroquinone lipids)	5.19 [1.11, 24.38]	0.037	-	VDAART
Retinol (Vitamin A) (Retinoids)	4.79 [1.03, 22.35]	0.046		VDAART
Sphingomyelin (d18:1/14:0, d16:1/16:0) (Phosphosphingolipids)	4.60 [1.13, 18.77]	0.033	├■-	VDAART
2,8-quinolinediol sulfate (Quinolones and derivatives)	3.23 [1.47, 7.14]	0.004	■	VDAART
1-oleoyl-GPI (18:1) (Glycerophosphoinositols)	3.13 [1.21, 8.07]	0.018	■	VDAART
Phytanate (Diterpenoids)	2.75 [1.02, 7.44]	0.047	∎	VDAART
Glyceric acid (Carbohydrates and carbohydrate conjugates)	1.48 [1.05, 2.06]	0.024	 ■	GACRS
N1-methyl-2-pyridone-5-carboxamide (Pyridinecarboxylic acids and derivatives)	0.53 [0.30, 0.95]	0.030	⊢ ∎−	GACRS
Palmitoyl-arachidonoyl-glycerol (16:0/20:4) (Diradylglycerols)	0.21 [0.06, 0.77]	0.018		VDAART
		C	0.008 0.030.06 0.13 0.25 0.5 1 2 4 8 Decreased FA Risk Increased F	3 16 32 FA Risk

294

Figure 2: Metabolomic profiling of Food Allergy in the GACRS and VDAART pediatric populations identifies altered

bile acid and histidine metabolic pathways. Plasma metabolites associated with food allergy using logistic regression
 within each cohort, adjusted for age, sex, and race (for VDAART only), identified 29 significant metabolites higher in

298 participants with food allergy (orange) and 9 significant metabolites higher in unaffected controls (yellow). Pathways with 3 or

more unique metabolites included bile acids and histidine metabolism. Metabolomic profiling for each cohort was conducted in

300 different laboratories, leading to some differences in annotation of metabolites.

Polyunsaturated fatty Acids (PUFAs), including arachidonic acid derivatives, decrease over time on OIT in all participants (PNOIT)

- After quality control measures, 529 named metabolites were available for analysis in the PNOIT cohort. 303 Analyzing metabolite trajectories over time, metabolites showed longitudinal differences associated with 304 OIT among all participants (Figure E1). Subclasses with the highest number of significant metabolites 305 306 included eicosanoids (17 significant metabolites decreased over time), glycerophosphocholines (14 307 significant metabolites increased and 2 decreased over time), and glycerophosphoethanolamines (9 significant metabolites increased and 1 decreased over time) (Figure 3a). Several subclasses were 308 notable in that all significant metabolites (and a majority of non-significant metabolites) in that class 309 310 changed in the same direction, including increasing triacylglycerols, decreasing linoleic acids, and decreasing eicosanoids over time on OIT. Chemical subclass pathway enrichment of the significant 311
- metabolites identified top subclasses including eicosanoids, (q= 2.4×10^{-20} , enrichment ratio=43), glycerophosphocholines (q= 1.4×10^{-13} , enrichment ratio=15), and steroid esters (q= 3.7×10^{-6} , enrichment
- ratio=33) (**Figure 3b**). Biological pathway enrichment analysis also identified a number of
- PUFA/eicosanoid related pathways, including arachidonic acid oxylipin metabolism (q=7.6x10⁻⁵, 13% of
- metabolites in pathway), metabolism of alpha-linolenic acid ($q=1.1x10^{-5}$, 35% of pathway), eicosanoid
- metabolism via lipooxygenases (LOX) (q=0.00072, 19% of pathway), and eicosanoid synthesis
- (q=0.02, 15%) of metabolites in pathway). Additionally, amino acids: histidine catabolism ($q=4.0x10^{-5}$,
- 319 35% of pathway), and sphingolipid metabolism (q=0.025, 21% of pathway) were also identified by
- 320 biological pathway enrichment.

Based on biological significance in other atopic diseases and key metabolites associated with food 321 allergy in GACRS and VDAART, we defined a set of key pathways of interest, including histidine 322 metabolism, bile acids, sphingolipids, and polyunsaturated fatty acids (PUFAs) including linoleic acid 323 derivatives and eicosanoids (Figure 3d, all significant metabolites in Figure E1b). Of note, bile acids 324 were not detected in association with asthma in the VDAART cohort. Among PUFAs, significant 325 decreases in all participants during OIT were detected among the eicosanoids, including leukotriene B3 326 327 and B4, lipoxin A4, and several HETEs/DiHETES (range of coefficients: -0.04 to -0.071, range of p values:1.9x10⁻⁷ to 0.0014). All linoleic acid derivatives, including linoleic acid, 13-HpODE, and 13-328 329 HODE decreased (range of coefficients: -0.062 to -0.015, range of p-values: 5.7x10⁻⁰⁷ to 0.035) and all detected sphingolipids increased over time on OIT (range of coefficients: 0.027 to 0.031, range of p 330 values: 0.017 to 0.036). No bile acid or main histidine pathway metabolites were identified as changing 331 332 over time on OIT.

333



Figure 3 – PNOIT: Metabolites associated with change over time in the entire cohort during OIT. (A) Subclasses of

significant (p<0.05) metabolites with the number of metabolites increasing (purple) and decreasing (green). The total number

of detected non-significant metabolites within each subclass is denoted in gray. Pathway enrichment analyses show (B)

337 enrichment ratios (ratio of observed significant metabolites divided by expected significant metabolites) of chemical subclasses

338 plotted by the FDR adjusted p-value plotted on a log10 scale, and (C) percent of significant metabolites divided by the total 339 metabolites within the pathway plotted by the FDR-adjusted p-value plotted on a log10 scale. In B & C, black line denotes

339 metabolites within the pathway plotted by the FDR-adjusted p-value plotted on a log10 scale. In B & C, black line denotes 340 g<0.05, and key pathways of interest are labeled in magenta (bile acids, eicosanoids, linoleic acids, sphingolipids, histidine</p>

341 metabolites). (D) Association of each metabolite with time on OIT.

Enrichment of bile acid, histidine, and eicosanoid pathways in sustained unresponsiveness in PNOIT

- Adjusting for time, 116 named metabolites (21.9% of total named metabolites) differed between
- individuals on OIT with sustained unresponsiveness compared to transient desensitization (Figure
- 346 E2a). Top subclasses, based on number of metabolites observed, included glycerophosphocholines (8
- higher in SU and 10 higher in TD, $q=6.8 \times 10^{-16}$; enrichment ratio=18) and amino acids, peptides, and
- analogues (12 higher in SU and 2 higher in TD, $q=7.9x10^{-7}$; enrichment ratio=6) (**Figure 4a**).
- 349 Subclasses that were notable because all significant metabolites (and a majority of non-significant
- 350 metabolites) in that class were higher in one group included all triacylglycerols higher in transient
- desensitization (6 metabolites), and all eicosanoid metabolites (8 metabolites) higher in sustained
- unresponsiveness. Chemical enrichment analysis identified differences in bile acid (q=4.1x10⁻⁸;
- enrichment ratio=33) and eicosanoid ($q=7.9x10^{-7}$; enrichment ratio=19) subclasses between the two
- groups (Figure 4b), and biological pathway enrichment (Figure 4c) showed significant enrichment of
- several bile acid pathways, including recycling of bile acids and salts ($q=2.0x10^{-7}$; 45% of pathway),
- transport of bile salts (q= 5.4×10^{-5} ; 15% of pathway), synthesis of bile acids and bile salts (q=0.00019;
- 18% of pathway), and primary bile acid synthesis (q=0.017; 17% of pathway), as well as, eicosanoid
 metabolism via lipooxygenases (LOX) (q=0.030; 9% of pathway), histidine catabolism (q=0.015; 14%)
- metabolism via lipooxygenases (LOX) (q=0.030; 9% of pathway), histidine catabolism (q=0.015; 14% of pathway), and sphingolipid metabolism (q=0.004; 9% of pathway). Among the curated set of
- pathways of interest, histidines (1 higher in SU, 1 with TD), bile acids (2 higher in SU and 5 with TD),
- eicosanoids (8 higher in SU), and linoleic acid metabolites (1 higher in TD) all contained metabolites
- 362 significantly associated with clinical outcome (**Figure 4d** & all significant metabolites in **Figure E2b**).



364 Figure 4 – PNOIT: Metabolites differing between participants who develop sustained

unresponsiveness (SU) compared to transient desensitization (TD). (A) Subclasses of significant (p<0.05) metabolites with the number of metabolites higher in either SU (blue) or TD (red). The total number of detected non-significant metabolites within each subclass is denoted in gray. Pathway enrichment analyses show (B) the ratio of observed significant metabolites divided by the number of expected metabolites within the chemical subclass plotted by the FDR-adjusted p-value plotted on a log10 scale, and (C) the percent of significant metabolites divided by the total metabolites within the biological pathway plotted by the FDR-adjusted p-value plotted on a log10 scale. In B & C, black line denotes q<0.05, and key pathways

- of interest are labeled in magenta (bile acids, eicosanoids, linoleic acids, sphingolipids, histidine metabolites). (D) Association
- of each metabolite with time on OIT.
- 373
- Among bile acids, most were higher in transient desensitization (range of OR: 0.12-0.36, range of
- p=0.00068-0.044), with two in particular higher in sustained unresponsiveness, lithocholate (OR: 4.97,
- p = 0.0027) and glycolithocholate (OR: 2.89, p = 0.034) (**Figure 4b**). For some metabolites,
- 377 ursodeoxycholate, alpha-muricholate, and ketodeoxycholate, trajectories differed at baseline, with
- higher levels among transiently desensitized individuals, and converged over time on OIT (**Figure 5a**).
- 379 For lithocholate, levels stayed relatively stable during OIT, with higher concentrations among
- 380 participants with sustained unresponsiveness, whereas the downstream metabolite glycolithocholate
- 381 demonstrated converging trajectories during OIT.
- 382 Among PUFAs, significant metabolites were detected from the eicosanoid subclass, including
- leukotriene B₃ (LTB₃) and LTB₄, lipoxin A₄ (LXA₄), 5,6-DHET (5,6-DiHETrE), and several
- HETES/DiHETES (range of OR: 2.80-10.83, range of p: 0.0039-0.024) (**Figure 4b**). With the exception
- of 5,6-DiHETrE/5,6-DHET, all eicosanoid metabolites decreased over time on OIT, with more dramatic
- decreases among those participants with transient desensitization than with sustained
- 387 unresponsiveness (**Figure 5b**).
- 388 For histidine metabolism, the 1-methylhistidine was higher in subjects with transient desensitization
- (OR: 0.20, p=0.039), whereas urocanic acid (OR: 22.13, p=0.0015), was higher among participants with
- 390 sustained unresponsiveness (**Figure 4b**). The histidine derivatives demonstrated higher
- concentrations at baseline and converged over time on therapy (**Figure 5c**). Meanwhile, urocanic acid
- 392 levels were similar between both groups of participants at baseline, and then diverged during OIT, most
- dramatically between baseline and buildup, with higher levels among participants with sustained
- 394 unresponsiveness.
- 395





404 Figure 5 – PNOIT: Overview of key metabolic pathways of interest and metabolite trajectories during OIT, between

transient desensitization (TD, red) and sustained unresponsiveness (SU, blue). A. Bile acid pathway. B. Histidine
 Pathway, C. Omega 3 fatty acids (PUFAs), D. Omega 6 fatty acids (PUFAs). Metabolites associated with food allergy are

406 Pathway. C. Omega 3 fatty acids (PUFAs). D. Omega 6 fatty acids (PUFAs). Metabolites associated with food allergy are 407 denoted in small boxes colored by orange (higher in food allergy) or yellow (higher in unaffected controls). Metabolites

407 associated with time on OIT in the entire cohort are denoted in small boxes in green (decreasing during OIT) or purple

409 (increasing during OIT). Modified derivatives of the main metabolite are listed under the main metabolite. Only metabolites that

410 significantly differ in association with food allergy and/or OIT are depicted, with major biosynthetic processes in thick arrows

- and simpler metabolic modifications in thin arrows. Graphs are only displayed for metabolites that differed significantly
- between SU & TD. Listed odds ratio and confidence interval (OR [95%CI]) statistics are derived from logistic regression
 models analyzing the association of the metabolite with OIT outcome (SU versus TD), adjusted for age and time on OIT.

414 **DISCUSSION**:

- 415 In this analysis of data from three studies including an international cohort, we conducted untargeted
- 416 metabolomic profiling of two epidemiologic cohorts and one interventional clinical trial to identify
- 417 metabolites associated with IgE-mediated food allergy and clinical responses to PNOIT. To our
- 418 knowledge, this is the first study of metabolomics in the setting of food allergen immunotherapy in
- 419 humans. In this analysis, we discovered a number of key metabolites (including bile acids and histidine
- 420 metabolites) associated with parental report of food allergy in GACRS, as well as with IgE-mediated
- food allergy in VDAART. In PNOIT, exploration of these pathways among participants with confirmed
- 422 IgE-mediated food allergy demonstrated that bile acids, eicosanoids, and histidine metabolites were
- 423 associated with differential responses to OIT, distinguishing individuals with transient desensitization to
- 424 OIT lasting only the duration of active treatment from those with sustained unresponsiveness with

425 protection lasting at least a month beyond the cessation of OIT.

426 The immunomodulatory roles of bile acids in food allergy and OIT

427 Elevated bile acids in food allergy

428 Our work showed significantly higher levels of bile acids among children with food allergy compared to 429 unaffected controls, replicating findings from another study of serum metabolomics in food allergy.¹⁴ 430 These bile acids however, were not associated with other atopic diseases, such as asthma in the 431 VDAART cohort. Other work in VDAART has shown that stool from children with food allergy is notable 432 for lower levels of bile acids compared to both unaffected controls and sensitized children (those with

- food specific antibodies but not food-allergy).^{13, 18} This work has been replicated in another study
- showing not only lower bile acids in stool from children with food allergy compared to healthy controls,
- but also lower levels of bile acids in children with persistent food allergy.⁴² Combined with our findings
 that children with food allergy in VDAART had higher levels of bile acids in the plasma, this suggests
- that children with food allergy in VDAART had higher levels of bile acids in the plasma, this suggests
 the increase in plasma bile acids is most likely due to increased bile acid reabsorption in food-allergy,
- rather than increased overall metabolism of bile acids by gut microbiota. Increased bile acid absorption
- has been implicated in the mechanism of liver diseases and type 2 diabetes mellitus, and increased
- bile acid levels have been linked to increases in intestinal permeability, notable because IgE-mediated
- food allergy is also marked by dysfunctions in intestinal permeability.^{43, 44}
- 442 Lower bile acids & and higher lithocholate derivatives in sustained efficacy on OIT
- 443 In addition to elevated levels in food allergy, our work shows generally higher levels of bile acids,
- especially deoxycholate derivatives, among individuals who only develop transient desensitization on

OIT (potentially a more severe phenotype of food allergy) (Figure 5a). The exceptions to this pattern,

- 446 lithocholate & glycolithocholate are higher among children who later develop sustained
- 447 unresponsiveness after stopping therapy. Given lithocholate derivatives actively alter T cell
- differentiation,^{45, 46} our data suggest that lithocholate is not only a biomarker but may actively increase
- the likelihood of allergic remission. These bile acid profiles seem to be present even before the
- 450 initiation of OIT, and while some bile acid trajectories converge over time on OIT, others, like
- 451 lithocholate remain relatively stable.

452 Immunomodulatory roles of lithocholate on the T cell subsets associated with OIT outcomes

Recent findings have uncovered many novel roles for bile acids in immune regulation of T cells.⁴⁷ Bile 453 acids are synthesized from cholesterol in the liver, secreted into the intestine to help with digestion. 454 modified by gut bacteria into secondary bile acids and then reabsorbed.⁴⁸ In murine models, a screen of 455 primary and secondary bile acids discovered that two lithocholate metabolites blocked Th17 456 differentiation and function and enhanced Treg differentiation, stability, and function.^{45, 46} Colonization 457 of mice with human bacterial strains that produce certain lithocholate derivatives can suppress Th17 458 levels and increase the gut Treg population. ^{46, 49} In human studies of OIT, decreases in peanut-specific 459 Th17 frequency have been observed between those who achieve desensitization compared to those 460 who fail treatment.¹⁵ as well as decreased overall Th17 frequency over time on OIT among older 461 462 children and teens.⁵⁰ While peripheral allergen-specific Treg frequencies do not differ by sustained unresponsiveness outcomes in OIT,^{15, 51} mucosal allergen-specific Treg responses have not been 463 studied, and OIT has been shown to induce increased expansion of the overall Treg compartment in 464 465 patients who develop sustained unresponsiveness, compared to those who develop transient desensitization.^{52, 53} We propose that bile acids, such as lithocholate derivatives, modulate T cell 466 percentages and function to increase the likelihood of remission in OIT. Overall, these findings may 467 reflect not only the microbial differences in individuals who develop longer lasting protection from OIT, 468 but also an active role for bile acids in mediating these immunopathogenic differences. 469

470 Altered histidine metabolism in food allergy and OIT

471 Our work demonstrated altered serum histidine metabolism in food allergy, with metabolites such as urocanic acid (UCA) and histidine were increased in those with food allergy while ergothioneine was 472 increased among unaffected controls. Others have also found altered histidine metabolism associated 473 with food allergy and food allergy development in both the serum and stool.^{14, 20} Histidine is an essential 474 475 amino acid that can be converted into both inflammatory mediators (e.g. histamine) but also antiinflammatory derivatives such as the cis-form of urocanic acid (UCA). In the skin, peanut allergic 476 children had lower levels of cis-UCA compared to non-atopic controls, independent of their atopic 477 dermatitis.⁵⁴ Given these findings, the elevation of UCA in food allergic children in GACRS is 478 unexpected, but may reflect differences between the isomers or between the plasma and skin 479 480 metabolome.

481 These data also demonstrate a role for histidine metabolites in OIT responses. In particular urocanic

acid (UCA) levels are higher in individuals with sustained unresponsiveness in PNOIT, though that

difference was apparently induced by OIT (**Figure 5b**). UCA has a number of immunomodulatory

- 484 functions, including increasing IL-10 expression, decreasing IFN-gamma production by antigen specific
- 485 T cells, and increasing Treg percentages.^{55, 56} IL-10 producing cells (including T regs, CD4+ T cells,

and regulatory B cells) are important for the development of allergic tolerance.⁸ Furthermore, our data 486 revealed higher levels of succinic acid in our participants with transient desensitization (Figure E2a, 487 Dicarboxylic Acids & Derivatives), and succinic acid inhibits histidase, the enzyme that converts 488 histidine into urocanic acid.⁵⁷ Both succinic acid and urocanic acid creation and degradation are 489 affected by skin and gut microbial flora,^{57, 58} all of which supports another potential pathway by which 490 the microbiome interacts with the immune system to effect tolerance on immunotherapy. Given the 491 known bidirectional nature of microbial-immune cross-talk,^{59, 60} this may provide a potential explanation 492 493 for why changes in urocanic acid do not occur until after OIT is initiated. Additionally, UCA is a 494 breakdown product of filagorin, a key epithelial barrier protein which is a risk factor for food allergy and is decreased in atopic dermatitis and eosinophilic esophagitis (EoE) but normalizes after treatment of 495 EoE.⁶¹⁻⁶³ Given the links between EoE, tissue eosinophilia, and OIT, the increase in UCA in sustained 496 unresponsiveness may reflect changes in filaggrin expression during OIT.⁶⁴ Overall, the divergence in 497 UCA trajectories between sustained unresponsiveness and transient desensitization suggest that the 498 role of UCA, as an immunomodulatory metabolite or as a reflection of changes in the microbiome or 499 500 filaggrin, merits further study.

501 Decreases in PUFAs during OIT

PUFAs (often described as omega-3 and omega-6 fatty acids) encompass a variety of subclasses of 502 metabolites, including eicosanoids and linoleic acid derivatives. Of these groups, eicosanoids (which 503 include arachidonic acid derivatives) have a well described role in the pathophysiology of allergic 504 505 disease, with many having an allergic pro-inflammatory role, including leukotrienes, and prostaglandins.⁶⁵ In our data, all measured eicosanoids and linoleic acid derivatives decreased over 506 time on OIT, and we hypothesize that the general decrease in these inflammatory mediators is a result 507 of reduced inflammatory circuits and successful treatment (Figure 5c). The finding that participants with 508 transient desensitization exhibited more dramatic decreases than those with sustained 509 unresponsiveness was unexpected. One potential explanation involves a key effector CD4 T cell 510 subset, referred to as pathogenic effector (peTh2)⁶⁶ or Th2A,⁶⁷ which has emerged as a likely regulator 511 of multiple allergic disease, including food allergy. These Th2A are notable for several features that 512 513 distinguish them from Th2-skewed T follicular helper cells (necessary for high-affinity IgE) and other Th2 subsets, including production of IL-9, expression of the transcriptional regulator PPARγ, and the 514 marked upregulation of a set of eicosanoid sensing and synthesizing genes. ⁶⁸⁻⁷² We and others have 515 shown that Th2A are suppressed by OIT in both TD and SU.^{15, 51} Recent data from cellular analysis of 516 young toddlers undergoing OIT also demonstrated that Th2A cells were suppressed over time by OIT, 517 and suggests one reason a decrease may be more dramatic in TD versus SU.⁵¹ For the one subject 518 analyzed who achieved SU, there were few Th2A cells present at baseline.⁵¹ Another possibility is that 519 these trajectories represent a shift between the arms of the eicosanoid pathway, where patients who go 520 on to develop sustained unresponsiveness, have a more dramatic decrease in prostaglandin 521 production. Prostaglandins were not detected in the plasma from these samples, but this merits further 522 study in future trials, ideally by the analysis of urine metabolites.

523

Limitations 524

525 This analysis compares three remarkably disparate populations: a cohort from Costa Rica, a country 526 with high prevalence of allergic asthma, a healthy cohort of US infants born to pregnant mothers from

527 an interventional trial of Vitamin D supplementation during pregnancy, and finally, children with food allergy treated with peanut OIT. These cohorts include ages ranging from toddlers to teenagers, and 528 children with varied allergic comorbidities. The diagnosis of IgE-mediated food allergy in these cohorts 529 was of variable stringency, with the PNOIT cohort having the most reliable diagnosis (confirmed by 530 531 clinician observed reactions to allergen), the VDAART population being most similar to a standard clinical cohort of IgE-mediated food allergy (diagnosed based on a combination of sensitization and 532 533 history, but often missing confirmatory food challenges) and GACRS cohort being the loosest, relying 534 on parentally reported food allergy. This work also faces limitations in the small sample sizes of 535 participants with food allergy. Because samples were being processed in parallel for isolation of cells. samples were not handled with strict temperature control required for ideal metabolomics processing 536 prior to freezing. This may have altered detection of certain metabolites. Furthermore, the 537 metabolomics profiling was conducted by two different groups, which is known to influence the 538 uniformity of metabolite detection, particularly notable in the replication of pathways between VDAART 539 and GACRS but not generally the exact metabolites. Despite these differences in study population and 540 metabolomics processing, we found replication of pathways between cohorts. Also our work supports 541 542 findings in the food allergy literature showing differential production of sphingolipids, tryptophan 543 metabolites, alanine metabolites, glycerophosphoinositols, and pyridine carboxylic acid derivatives (also described as Vitamin B3 metabolites).^{14, 73} Furthermore, many of the pathways associated with 544 food allergy were differentially produced when comparing the two clinical responses to OIT, adding 545 robustness to the hypothesis that these metabolites represent an important part of the immune 546

547 pathogenesis of IgE-mediated food allergy.

548 Conclusion

In summary, we have identified key metabolite pathways associated with food allergy and differential responses to OIT. Many of these metabolites, including bile acids, eicosanoids, and histidine/urocanic acid, have active roles in modulating the same T cell subsets that are thought to mediate remission in allergen immunotherapy. Further functional validation of these metabolic pathways in the context of allergic tolerance may both help identify patients most likely to benefit from OIT and guide the development of adjunctive therapies that can improve outcomes of allergen immunotherapy.

555

556 **References**

557 1. Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, Schleimer RP, Nadeau KC. Prevalence and Severity of Food Allergies Among US Adults. JAMA Netw Open. 558 2019;2(1):e185630. Epub 2019/01/16. doi: 10.1001/jamanetworkopen.2018.5630. PubMed PMID: 559 560 30646188; 561 2. Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, Nadeau KC. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. Pediatrics. 562 2018;142(6). Epub 2018/11/21. doi: 10.1542/peds.2018-1235. PubMed PMID: 30455345; 563 564 Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 3. 2009;124(6):1549-55. Epub 2009/11/18. doi: 10.1542/peds.2009-1210. PubMed PMID: 19917585; 565 Pepper AN, Assa'ad A, Blaiss M, Brown E, Chinthrajah S, Ciaccio C, Fasano MB, Gupta R, 566 4. 567 Hong N, Lang D, Mahr T, Malawer E, Roach A, Shreffler W, Sicherer S, Vickers K, Vickery BP, Wasserman R, Yates K, Casale TB. Consensus report from the Food Allergy Research & Education 568 569 (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. J Allergy Clin Immunol. 2020;146(2):244-9. Epub 2020/06/09. doi: 10.1016/j.jaci.2020.05.027. PubMed PMID: 32505612; 570 Nowak-Wegrzyn A, Sampson HA. Future therapies for food allergies. J Allergy Clin Immunol. 571 5. 2011;127(3):558-73; quiz 74-5. Epub 2011/02/01. doi: 10.1016/j.jaci.2010.12.1098. PubMed PMID: 572 573 21277625: Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, Manohar M, Boyd SD, 574 6. Tibshirani R, Maecker H, Plaut M, Mukai K, Tsai M, Desai M, Galli SJ, Nadeau KC. Sustained 575 outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, 576 577 placebo-controlled, phase 2 study. Lancet. 2019;394(10207):1437-49. Epub 2019/09/17. doi: 578 10.1016/S0140-6736(19)31793-3. PubMed PMID: 31522849; Kazmi W, Berin MC. Oral tolerance and oral immunotherapy for food allergy: Evidence for 579 7. 580 common mechanisms? Cell Immunol. 2023;383:104650. Epub 2022/12/22. doi: 10.1016/j.cellimm.2022.104650. PubMed PMID: 36543052; 581 Barshow SM, Kulis MD, Burks AW, Kim EH, Mechanisms of oral immunotherapy, Clin Exp. 582 8. Allergy. 2021;51(4):527-35. Epub 2021/01/09. doi: 10.1111/cea.13824. PubMed PMID: 33417257; 583 Sindher SB, Chin AR, Aghaeepour N, Prince L, Maecker H, Shaw GM, Stevenson DK, Nadeau 584 9. 585 KC, Snyder M, Khatri P, Boyd SD, Winn VD, Angst MS, Chinthrajah RS. Advances and potential of omics studies for understanding the development of food allergy. Front Allergy. 2023;4:1149008. Epub 586 2023/04/11. doi: 10.3389/falgy.2023.1149008. PubMed PMID: 37034151; 587 588 10. Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003;2(8):668-76. PubMed PMID: 12904817; 589 590 11. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV, van Dam K, Oliver SG. A functional genomics strategy that 591 uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol. 2001;19(1):45-50. 592 593 doi: 10.1038/83496. PubMed PMID: 11135551; 594 12. Kong J, Chalcraft K, Mandur TS, Jimenez-Saiz R, Walker TD, Goncharova S, Gordon ME, Naji 595 L, Flader K, Larche M, Chu DK, Waserman S, McCarry B, Jordana M. Comprehensive metabolomics 596 identifies the alarmin uric acid as a critical signal for the induction of peanut allergy. Allergy. 597 2015;70(5):495-505. doi: 10.1111/all.12579. PubMed PMID: 25647422; Lee-Sarwar KA, Chen YC, Lasky-Su J, Kelly RS, Zeiger RS, O'Connor GT, Bacharier LB. Jia X. 598 13. Beigelman A, Gold DR, Laranjo N, Bunyavanich S, Weiss ST, Litonjua AA, Brennan PJ. Early-life fecal 599 600 metabolomics of food allergy. Allergy. 2023;78(2):512-21. Epub 2022/12/01. doi: 10.1111/all.15602. 601 PubMed PMID: 36448508; Crestani E, Harb H, Charbonnier LM, Leirer J, Motsinger-Reif A, Rachid R, Phipatanakul W, 602 14. Kaddurah-Daouk R, Chatila TA. Untargeted metabolomic profiling identifies disease-specific signatures 603 604 in food allergy and asthma. J Allergy Clin Immunol. 2020;145(3):897-906. Epub 2019/11/02. doi:

605 10.1016/j.jaci.2019.10.014. PubMed PMID: 31669435;

606 15. Monian B. Tu AA. Ruiter B. Morgan DM. Petrossian PM. Smith NP. Gierahn TM. Ginder JH. Shreffler WG, Love JC. Peanut oral immunotherapy differentially suppresses clonally distinct subsets of 607 608 T helper cells. J Clin Invest. 2022;132(2). Epub 2021/11/24. doi: 10.1172/JCI150634. PubMed PMID: 609 34813505; Xie S, Jiang S, Zhang H, Wang F, Liu Y, She Y, Jing Q, Gao K, Fan R, Xie S, Xie Z, Jiang W. 610 16. 611 Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis. Int Immunopharmacol. 2021;90:107211. Epub 2020/12/04. doi: 10.1016/j.intimp.2020.107211. PubMed 612 613 PMID: 33271394: 614 17. Zheng P, Yan G, Zhang Y, Huang H, Luo W, Xue M, Li N, Wu JL, Sun B. Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous 615 Immunotherapy. Metabolites. 2021;11(9). Epub 2021/09/27. doi: 10.3390/metabo11090613. PubMed 616 617 PMID: 34564431; Lee-Sarwar K, Kelly RS, Lasky-Su J, Moody DB, Mola AR, Cheng TY, Comstock LE, Zeiger RS, 618 18. O'Connor GT, Sandel MT, Bacharier LB, Beigelman A, Laranjo N, Gold DR, Bunyavanich S, Savage 619 JH. Weiss ST. Brennan PJ. Litoniua AA. Intestinal microbial-derived sphingolipids are inversely 620 associated with childhood food allergy. J Allergy Clin Immunol. 2018;142(1):335-8 e9. Epub 621 2018/05/08. doi: 10.1016/j.jaci.2018.04.016. PubMed PMID: 29729303; 622 623 Savage JH, Lee-Sarwar KA, Sordillo J, Bunyavanich S, Zhou Y, O'Connor G, Sandel M, 19. 624 Bacharier LB, Zeiger R, Sodergren E, Weinstock GM, Gold DR, Weiss ST, Litonjua AA. A prospective 625 microbiome-wide association study of food sensitization and food allergy in early childhood. Allergy. 2018;73(1):145-52. Epub 2017/06/21. doi: 10.1111/all.13232. PubMed PMID: 28632934; 626 Chun Y, Grishin A, Rose R, Zhao W, Arditi Z, Zhang L, Wood RA, Burks AW, Jones SM, Leung 627 20. 628 DYM, Jones DR, Sampson HA, Sicherer SH, Bunyavanich S. Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development. J Allergy Clin Immunol. 2023;152(6):1569-629 80. Epub 2023/08/25. doi: 10.1016/j.jaci.2023.08.012. PubMed PMID: 37619819; 630 Bunyavanich S, Becker PM, Altman MC, Lasky-Su J, Ober C, Zengler K, Berdyshev E, 631 21. Bonneau R, Chatila T, Chatterjee N, Chung KF, Cutcliffe C, Davidson W, Dong G, Fang G, Fulkerson 632 633 P, Himes BE, Liang L, Mathias RA, Ogino S, Petrosino J, Price ND, Schadt E, Schofield J, Seibold MA, Steen H, Wheatley L, Zhang H, Togias A, Hasegawa K. Analytical Challenges in Omics Research on 634 Asthma and Allergy: A National Institute of Allergy and Infectious Diseases Workshop. J Allergy Clin 635 636 Immunol. 2024. Epub 2024/02/01. doi: 10.1016/j.jaci.2024.01.014. PubMed PMID: 38295882; 22. Shibata R, Itoh N, Nakanishi Y, Kato T, Suda W, Nagao M, group JO, Iwata T, Yoshida H, 637 638 Hattori M, Fujisawa T, Shimojo N, Ohno H. Gut microbiota and fecal metabolites in sustained unresponsiveness by oral immunotherapy in school-age children with cow's milk allergy. Allergol Int. 639 2024;73(1):126-36. Epub 2024/01/06. doi: 10.1016/j.alit.2023.10.001. PubMed PMID: 38182280; 640 641 23. Pearce N, Aït-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C, the IPTSG. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma 642 643 and Allergies in Childhood (ISAAC). Thorax. 2007;62(9):758-66. doi: 10.1136/thx.2006.070169. PubMed PMID: PMC2117323; 644 645 24. Celedon JC, Soto-Quiros ME, Silverman EK, Hanson L, Weiss ST. Risk factors for childhood 646 asthma in Costa Rica. Chest. 2001;120(3):785-90. Epub 2001/09/14. doi: 10.1378/chest.120.3.785. PubMed PMID: 11555510; 647 Hunninghake GM, Soto-Quiros ME, Avila L, Ly NP, Liang C, Sylvia JS, Klanderman BJ, 648 25. 649 Silverman EK, Celedon JC. Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica. J Allergy Clin Immunol. 2007;119(3):654-61. Epub 2007/03/06. doi: 650 651 10.1016/j.jaci.2006.12.609. PubMed PMID: 17336615; 26. Hunninghake GM, Soto-Quiros ME, Avila L, Kim HP, Lasky-Su J, Rafaels N, Ruczinski I, Beaty 652 TH, Mathias RA, Barnes KC, Wilk JB, O'Connor GT, Gauderman WJ, Vora H, Baurley JW, Gilliland F, 653 Liang C, Sylvia JS, Klanderman BJ, Sharma SS, Himes BE, Bossley CJ, Israel E, Raby BA, Bush A, 654

655 Choi AM, Weiss ST, Celedon JC. TSLP polymorphisms are associated with asthma in a sex-specific

656 fashion. Allergy. 2010;65(12):1566-75. Epub 2010/06/22. doi: 10.1111/j.1398-9995.2010.02415.x. PubMed PMID: 20560908; 657 658 27. Litonjua AA, Lange NE, Carey VJ, Brown S, Laranjo N, Harshfield BJ, O'Connor GT, Sandel M, 659 Strunk RC, Bacharier LB, Zeiger RS, Schatz M, Hollis BW, Weiss ST. The Vitamin D Antenatal Asthma Reduction Trial (VDAART): rationale, design, and methods of a randomized, controlled trial of vitamin D 660 661 supplementation in pregnancy for the primary prevention of asthma and allergies in children. Contemp Clin Trials. 2014;38(1):37-50. Epub 2014/03/13. doi: 10.1016/j.cct.2014.02.006. PubMed PMID: 662 663 24614387: Patil SU, Steinbrecher J, Calatroni A, Smith N, Ma A, Ruiter B, Virkud Y, Schneider M, Shreffler 664 28. WG. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after 665 peanut oral immunotherapy. J Allergy Clin Immunol. 2019;144(5):1310-9 e4. Epub 2019/08/05. doi: 666 667 10.1016/j.jaci.2019.07.028. PubMed PMID: 31377342; Blumenthal MN, Banks-Schlegel S, Bleecker ER, Marsh DG, Ober C. Collaborative studies on 668 29. the genetics of asthma—National Heart, Lung and Blood Institute. Clinical & Experimental Allergy. 669 1995:25:29-32. doi: 10.1111/i.1365-2222.1995.tb00416.x: 670 Kelly RS, Virkud Y, Giorgio R, Celedon JC, Weiss ST, Lasky-Su J. Metabolomic profiling of lung 671 30. function in Costa-Rican children with asthma. Biochim Biophys Acta Mol Basis Dis. 2017;1863(6):1590-672 5. Epub 2017/02/12. doi: 10.1016/j.bbadis.2017.02.006. PubMed PMID: 28188833; 673 674 Kelly RS, Sordillo JE, Lasky-Su J, Dahlin A, Perng W, Rifas-Shiman SL, Weiss ST, Gold DR, 31. 675 Litonjua AA, Hivert MF, Oken E, Wu AC. Plasma metabolite profiles in children with current asthma. Clin Exp Allergy. 2018;48(10):1297-304. Epub 2018/05/29. doi: 10.1111/cea.13183. PubMed PMID: 676 29808611; 677 678 32. Zhang B, Hu S, Baskin E, Patt A, Siddigui JK, Mathe EA. RaMP: A Comprehensive Relational 679 Database of Metabolomics Pathways for Pathway Enrichment Analysis of Genes and Metabolites. Metabolites. 2018;8(1). Epub 2018/02/23. doi: 10.3390/metabo8010016. PubMed PMID: 29470400; 680 681 33. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, 682 683 Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, 684 Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. Nucleic 685 Acids Res. 2007;35(Database issue):D521-6. Epub 2007/01/05. doi: 10.1093/nar/gkl923. PubMed 686 PMID: 17202168; 687 688 34. Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, Berjanskii M, Mah R, Yamamoto M, Jovel J, Torres-Calzada C, Hiebert-Giesbrecht M, Lui VW, 689 Varshavi D, Varshavi D, Allen D, Arndt D, Khetarpal N, Sivakumaran A, Harford K, Sanford S, Yee K, 690 691 Cao X, Budinski Z, Liigand J, Zhang L, Zheng J, Mandal R, Karu N, Dambrova M, Schioth HB, Greiner R, Gautam V. HMDB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res. 692 2022;50(D1):D622-D31. Epub 2022/01/07. doi: 10.1093/nar/gkab1062. PubMed PMID: 34986597: 693 35. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, 694 Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, 695 696 Varusai T, Weiser J, Wu G, Stein L, Hermiakob H, D'Eustachio P. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48(D1):D498-D503. Epub 2019/11/07. doi: 697 10.1093/nar/gkz1031. PubMed PMID: 31691815; 698 Agrawal A, Balci H, Hanspers K, Coort SL, Martens M, Slenter DN, Ehrhart F, Digles D, 699 36. Waagmeester A, Wassink I, Abbassi-Daloii T, Lopes EN, Iyer A, Acosta JM, Willighagen LG, Nishida K, 700 Riutta A, Basaric H, Evelo CT, Willighagen EL, Kutmon M, Pico AR. WikiPathways 2024: next 701 702 generation pathway database. Nucleic Acids Res. 2024;52(D1):D679-D89. Epub 2023/11/09. doi: 10.1093/nar/gkad960. PubMed PMID: 37941138; 703 Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck 704 37. 705 C, Subramanian S, Bolton E, Greiner R, Wishart DS. ClassyFire: automated chemical classification with

706 a comprehensive, computable taxonomy, J Cheminform, 2016:8:61, Epub 2016/11/22, doi: 707 10.1186/s13321-016-0174-y. PubMed PMID: 27867422; R Core Team. R: A language and environment for statistical computing. R Foundation for 708 38. 709 Statistical Computing [Internet]. 2018. Available from: https://www.R-project.org/. dbGaP/database of Genotypes and Phenotypes/ National Center for Biotechnology Information, 710 39. 711 National Library of Medicine (NCBI/NLM). Available from: /https://www.ncbi.nlm.nih.gov/gap. 40. ECHO Cohort Data; 712 Metabolomics Workbench: 713 41. 714 42. Lee SY, Park YM, Yoo HJ, Lee SH, Choi EJ, Baek EY, Song KB, Yoon J, Hong SJ. The alternative bile acid pathway can predict food allergy persistence in early childhood. Pediatr Allergy 715 Immunol. 2023;34(8):e14003. Epub 2023/08/25. doi: 10.1111/pai.14003. PubMed PMID: 37622258; 716 717 43. Ticho AL, Malhotra P, Dudeja PK, Gill RK, Alrefai WA. Intestinal Absorption of Bile Acids in 718 Health and Disease. Compr Physiol. 2019;10(1):21-56. Epub 2019/12/20. doi: 10.1002/cphy.c190007. 719 PubMed PMID: 31853951; Calzadilla N. Comiskey SM. Dudeia PK. Saksena S. Gill RK. Alrefai WA. Bile acids as 720 44. 721 inflammatory mediators and modulators of intestinal permeability. Front Immunol. 2022;13:1021924. Epub 2022/12/27. doi: 10.3389/fimmu.2022.1021924. PubMed PMID: 36569849; 722 723 Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, Zheng Y, 45. 724 Longman RS, Rastinejad F, Devlin AS, Krout MR, Fischbach MA, Littman DR, Huh JR. Bile acid 725 metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576(7785):143-8. Epub 726 2019/11/30. doi: 10.1038/s41586-019-1785-z. PubMed PMID: 31776512; Paik D, Yao L, Zhang Y, Bae S, D'Agostino GD, Zhang M, Kim E, Franzosa EA, Avila-Pacheco 727 46. 728 J, Bisanz JE, Rakowski CK, Vlamakis H, Xavier RJ, Turnbaugh PJ, Longman RS, Krout MR, Clish CB, Rastinejad F, Huttenhower C, Huh JR, Devlin AS. Human gut bacteria produce Tau(Eta)17-modulating 729 730 bile acid metabolites. Nature. 2022;603(7903):907-12. Epub 2022/03/18. doi: 10.1038/s41586-022-731 04480-z. PubMed PMID: 35296854; Kiriyama Y, Nochi H. The Role of Gut Microbiota-Derived Lithocholic Acid, Deoxycholic Acid 732 47. 733 and Their Derivatives on the Function and Differentiation of Immune Cells. Microorganisms. 2023;11(11). Epub 2023/11/25. doi: 10.3390/microorganisms11112730. PubMed PMID: 38004742; 734 Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191-212. Epub 735 48. 736 2013/07/31. doi: 10.1002/cphy.c120023. PubMed PMID: 23897684; Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist 737 49. 738 C, Kasper DL. Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature. 2020;577(7790):410-5. Epub 2019/12/27. doi: 10.1038/s41586-019-1865-0. 739 740 PubMed PMID: 31875848; 741 50. Luce S, Chinthrajah S, Lyu SC, Nadeau KC, Mascarell L. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy. 742 743 Allergy. 2020;75(6):1513-6. Epub 2020/01/14. doi: 10.1111/all.14180. PubMed PMID: 31930521; Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon LB, Aldridge K, Rosasco M, 744 51. Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, 745 Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT, 746 Wambre E, Impact. Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals 747 undergoing oral immunotherapy. J Allergy Clin Immunol. 2023;152(1):155-66 e9. Epub 2023/04/02. doi: 748 749 10.1016/j.jaci.2023.03.020. PubMed PMID: 37003475; Lozano-Ojalvo D, Tyler SR, Aranda CJ, Wang J, Sicherer S, Sampson HA, Wood RA, Burks 750 52. AW, Jones SM, Leung DYM, de Lafaille MC, Berin MC. Allergen recognition by specific effector Th2 751 752 cells enables IL-2-dependent activation of regulatory T-cell responses in humans. Allergy. 2023;78(3):697-713. Epub 2022/09/13. doi: 10.1111/all.15512. PubMed PMID: 36089900; 753 Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H, 754 53. O'Riordan G, Galli SJ, Nadeau KC. Peanut oral immunotherapy results in increased antigen-induced 755 regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin 756

757 Immunol. 2014;133(2):500-10. Epub 2014/03/19. doi: 10.1016/j.jaci.2013.12.1037. PubMed PMID: 24636474; 758 759 54. Berdyshev E, Goleva E, Bronova I, Bronoff AS, Hoffman BC, Ramirez-Gama MA, Garcia SL, 760 Crumrine D, Elias PM, Cho CB, Leung DYM. Unique skin abnormality in patients with peanut allergy but no atopic dermatitis. J Allergy Clin Immunol. 2021;147(1):361-7 e1. Epub 2020/07/03. doi: 761 762 10.1016/j.jaci.2020.06.015. PubMed PMID: 32615171; 55. Correale J, Farez MF. Modulation of multiple sclerosis by sunlight exposure: role of cis-urocanic 763 acid. J Neuroimmunol. 2013;261(1-2):134-40. Epub 2013/06/27. doi: 10.1016/j.jneuroim.2013.05.014. 764 765 PubMed PMID: 23800457; Holan V, Kuffova L, Zajicova A, Krulova M, Filipec M, Holler P, Jancarek A. Urocanic acid 766 56. enhances IL-10 production in activated CD4+ T cells. J Immunol. 1998;161(7):3237-41. Epub 767 768 1998/10/06. PubMed PMID: 9759837; 769 Lessie TG, Neidhardt FC. Formation and operation of the histidine-degrading pathway in 57. Pseudomonas aeruginosa. J Bacteriol. 1967;93(6):1800-10. Epub 1967/06/01. doi: 770 10.1128/ib.93.6.1800-1810.1967. PubMed PMID: 4290562: 771 772 Hart PH, Norval M. The Multiple Roles of Urocanic Acid in Health and Disease. J Invest 58. 773 Dermatol. 2021;141(3):496-502. Epub 2020/09/14. doi: 10.1016/j.jid.2020.07.017. PubMed PMID: 774 32919759: 775 Sutherland DB, Suzuki K, Fagarasan S. Fostering of advanced mutualism with gut microbiota by 59. 776 Immunoglobulin A. Immunol Rev. 2016;270(1):20-31. Epub 2016/02/13. doi: 10.1111/imr.12384. 777 PubMed PMID: 26864102: Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and 778 60. 779 disease. Cell Res. 2020;30(6):492-506. Epub 2020/05/21. doi: 10.1038/s41422-020-0332-7. PubMed 780 PMID: 32433595; 781 61. Huffaker MF, Kanchan K, Bahnson HT, Baloh C, Lack G, Nepom GT, Mathias RA. Incorporating 782 genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial. J Allergy Clin Immunol. 2023;151(4):841-7. Epub 2023/02/03. doi: 783 784 10.1016/i.iaci.2022.12.819. PubMed PMID: 36732171: Politi E, Angelakopoulou A, Grapsa D, Zande M, Stefanaki K, Panagiotou I, Roma E, Syrigou E. 785 62. Filaggrin and Periostin Expression Is Altered in Eosinophilic Esophagitis and Normalized With 786 787 Treatment. J Pediatr Gastroenterol Nutr. 2017;65(1):47-52. Epub 2017/06/24. doi: 10.1097/MPG.000000000001419. PubMed PMID: 28644349; 788 Nagano N, Araki A, Ishikawa N, Nagase M, Adachi K, Ishimura N, Ishihara S, Kinoshita Y, 789 63. 790 Maruyama R. Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor nonresponders compared with proton pump inhibitor responders of eosinophilic esophagitis. Esophagus. 791 792 2021;18(2):362-71. Epub 2020/09/11. doi: 10.1007/s10388-020-00781-2. PubMed PMID: 32909083; 793 Wright BL, Fernandez-Becker NQ, Kambham N, Purington N, Cao S, Tupa D, Zhang W, 64. 794 Sindher SB. Rank MA. Kita H. Katzka DA. Shim KP. Bunning BJ. Dovle AD. Jacobsen EA. Tsai M. 795 Boyd SD, Manohar M, Chinthrajah RS. Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy. Clin Gastroenterol Hepatol. 2021;19(6):1151-9 e14. 796 Epub 2020/05/21. doi: 10.1016/j.cqh.2020.05.019. PubMed PMID: 32434067; 797 Duan J, Song Y, Zhang X, Wang C. Effect of omega-3 Polyunsaturated Fatty Acids-Derived 798 65. 799 Bioactive Lipids on Metabolic Disorders. Front Physiol. 2021;12:646491. Epub 2021/06/12. doi: 800 10.3389/fphys.2021.646491. PubMed PMID: 34113260; Mitson-Salazar A, Yin Y, Wansley DL, Young M, Bolan H, Arceo S, Ho N, Koh C, Milner JD, 801 66. Stone KD, Wank SA, Prussin C. Hematopoietic prostaglandin D synthase defines a proeosinophilic 802

pathogenic effector human T(H)2 cell subpopulation with enhanced function. J Allergy Clin Immunol. 2016;137(3):907-18 e9. Epub 2015/10/04. doi: 10.1016/j.jaci.2015.08.007. PubMed PMID: 26431580;

67. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, Gersuk VH, DeBerg HA,

Whalen E, Ni C, Farrington M, Jeong D, Robinson D, Linsley PS, Vickery BP, Kwok WW. A

807 phenotypically and functionally distinct human T(H)2 cell subpopulation is associated with allergic

disorders. Sci Transl Med. 2017;9(401). Epub 2017/08/05. doi: 10.1126/scitranslmed.aam9171.
 PubMed PMID: 28768806;

810 68. Morgan DM, Ruiter B, Smith NP, Tu AA, Monian B, Stone BE, Virk-Hundal N, Yuan Q, Shreffler 811 WG, Love JC. Clonally expanded, GPR15-expressing pathogenic effector T(H)2 cells are associated

with eosinophilic esophagitis. Sci Immunol. 2021;6(62). Epub 2021/08/15. doi:

813 10.1126/sciimmunol.abi5586. PubMed PMID: 34389613;

814 69. Bertschi NL, Bazzini C, Schlapbach C. The Concept of Pathogenic TH2 Cells: Collegium
815 Internationale Allergologicum Update 2021. Int Arch Allergy Immunol. 2021;182(5):365-80. Epub
816 2021/04/13. doi: 10.1159/000515144. PubMed PMID: 33845475;

70. Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, Joseph J, Gertie JA, Xu L, Collet

MA, Grassmann JDS, Simoneau T, Chiang D, Berin MC, Craft JE, Weinstein JS, Williams A,

Eisenbarth SC. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science.
 2019;365(6456). Epub 2019/08/03. doi: 10.1126/science.aaw6433. PubMed PMID: 31371561;

71. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, Gersuk VH, DeBerg HA,

Whalen E, Ni C, Farrington M, Jeong D, Robinson D, Linsley PS, Vickery BP, Kwok WW. A

phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic

disorders. Sci Transl Med. 2017;9(401). doi: 10.1126/scitranslmed.aam9171. PubMed PMID:
 28768806;

72. Micosse C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, Seyed Jafari SM, Olah P, Yawlkar N, Simon D, Borradori L, Kuchen S, Yerly D, Homey B, Conrad C, Snijder B, Schmidt M,

Schlapbach C. Human "T(H)9" cells are a subpopulation of PPAR-gamma(+) T(H)2 cells. Sci Immunol.

2019;4(31). Epub 2019/01/20. doi: 10.1126/sciimmunol.aat5943. PubMed PMID: 30658968;

73. Jang H, Kim EG, Kim M, Kim SY, Kim YH, Sohn MH, Kim KW. Metabolomic profiling revealed

altered lipid metabolite levels in childhood food allergy. J Allergy Clin Immunol. 2022;149(5):1722-31

e9. Epub 2021/11/30. doi: 10.1016/j.jaci.2021.10.034. PubMed PMID: 34843802;

833